Quarterly ResultMay 8, 2026, 07:16 AM
Treace Medical Concepts Q1 Revenue Down 10.2% to $47.2M; Net Loss Widens
AI Summary
Treace Medical Concepts reported a significant decline in Q1 2026 revenue, falling 10.2% to $47.198 million, and a wider net loss of $17.961 million compared to the prior year. Despite a decrease in total operating expenses and an increase in net cash provided by operating activities, the company's core financial performance deteriorated. The company also adjusted the useful life of its surgical instruments, which reduced depreciation expense by $1.2 million for the quarter, and secured a new $125 million term loan facility, drawing $60 million.
Key Highlights
- Q1 2026 revenue decreased 10.2% to $47.198 million from $52.570 million in Q1 2025.
- Net loss widened to $17.961 million in Q1 2026 from $15.922 million in Q1 2025.
- Diluted net loss per share increased to $0.28 in Q1 2026 from $0.25 in Q1 2025.
- Total operating expenses decreased to $54.574 million from $57.475 million year-over-year.
- Net cash provided by operating activities increased to $7.240 million from $4.198 million.
- Adjusted useful life of capitalized surgical instruments from 3 to 5 years, reducing Q1 depreciation by $1.2M.
- Secured new 5-year term loan facility of up to $125 million, with $60 million drawn.
Price Impact
More from TMCI